Keros Therapeutics Reports Q1 Loss, Takeda Advances Elritercept to Phase 3
KROS is trading near its 52-week low of $10.415 (14% above the low).
Summary
Keros Therapeutics reported a Q1 2026 net loss but announced its partner Takeda will advance elritercept into a Phase 3 clinical trial, alongside a strong cash runway into mid-2028.
Key Events · Earnings and Guidance · KROS
-
Q1 2026 Net Loss Reported
Keros Therapeutics reported a net loss of $23.7 million, or $1.21 per share, for the first quarter of 2026, compared to a net income of $148.5 million in Q1 2025.
-
Elritercept Advances to Phase 3
Partner Takeda Pharmaceuticals plans to advance elritercept into a Phase 3 clinical trial to evaluate it as a treatment for anemia in myelofibrosis.
-
Strong Cash Runway Confirmed
The company's cash and cash equivalents stood at $281.5 million as of March 31, 2026, which is expected to fund operating expenses and capital expenditure requirements into the first half of 2028.
-
Reduced Research and Development Expenses
Research and development expenses decreased to $16.1 million for Q1 2026, primarily due to the transition of elritercept-related expenses to Takeda and a corporate restructuring completed in 2025.
Analysis · KROS · Life Sciences
Keros Therapeutics reported a net loss for Q1 2026, a reversal from the prior year's income which was significantly boosted by a Takeda license payment. Despite this, the company maintains a strong cash position, providing a runway into the first half of 2028. Critically, its partner Takeda plans to advance elritercept into a Phase 3 clinical trial for anemia in myelofibrosis, which is a significant de-risking and validation event for a key pipeline asset and reduces Keros's future R&D burden.
At the time of this filing, KROS was trading at $11.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $237.3M. The 52-week trading range was $10.42 to $22.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.